A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab

• Status: Terminated
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

The primary purpose of this study is to identify the maximum tolerated dose (MTD) of both intravenous and oral panobinostat plus trastuzumab. The study will evaluate safety and efficacy of the combination in adult female patients with HER2+ metastatic breast cancer

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Panobinostat; Trastuzumab

Criteria

Key Inclusion criteria:

• Age > 18 year old

• Confirmed HER2+ ve metastatic breast cancer

• Prior treatment and progression on trastuzumab

• Patients must have adequate laboratory values

• Eastern Cooperative Oncology Group (ECOG) performance status of <2

Key Exclusion criteria:

• Patients with active central nervous system (CNS) disease or brain metastases except those who have been previously treated and have been stable for at least 3 months.

• Impaired heart function or clinically significant heart disease

• Impairment of gastrointestinal (GI) function, or GI disease that may significantly alter the absorption of LBH589

• Ongoing diarrhea

• Liver or renal disease with impaired hepatic or renal functions

• Concomitant use of any anti-cancer therapy or certain drugs

• Female patients who are pregnant or breast feeding

• Patients not willing to use an effective method of birth control